Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616447 | 0.84 | KDM4E (0.52) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL30471977 | 0.82 | KDM4E (0.43) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL29868032 | 0.82 | PDK2 (0.45) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL30471931 | 0.82 | KDM4E (0.44) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL31708133 | 0.82 | KDM4E (0.43) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL25418887 | 0.82 | KDM4E (0.43) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL25216340 | 0.81 | KDM4E (0.42) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL23797047 | 0.81 | KDM4E (0.53) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL13266980 | 0.78 | KDM4E (0.46) | KDM4EGAAPDPK1CYP3A4CYP1A2 | |
| SCHEMBL20132900 | 0.77 | KDM4E (0.44) | KDM4EGAAPDPK1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2638014-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR ACTIVITY AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064744-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORϒ ACTIVITY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | KDM4E 2286/4885GAA 1571/4885PDPK1 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.